209 related articles for article (PubMed ID: 31950503)
41. NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages.
Venter G; Oerlemans FT; Willemse M; Wijers M; Fransen JA; Wieringa B
PLoS One; 2014; 9(5):e97378. PubMed ID: 24824795
[TBL] [Abstract][Full Text] [Related]
42. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
[TBL] [Abstract][Full Text] [Related]
43. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Bruzzone S; Fruscione F; Morando S; Ferrando T; Poggi A; Garuti A; D'Urso A; Selmo M; Benvenuto F; Cea M; Zoppoli G; Moran E; Soncini D; Ballestrero A; Sordat B; Patrone F; Mostoslavsky R; Uccelli A; Nencioni A
PLoS One; 2009 Nov; 4(11):e7897. PubMed ID: 19936064
[TBL] [Abstract][Full Text] [Related]
44. The NAD(+) salvage pathway modulates cancer cell viability via p73.
Sharif T; Ahn DG; Liu RZ; Pringle E; Martell E; Dai C; Nunokawa A; Kwak M; Clements D; Murphy JP; Dean C; Marcato P; McCormick C; Godbout R; Gujar SA; Lee PW
Cell Death Differ; 2016 Apr; 23(4):669-80. PubMed ID: 26586573
[TBL] [Abstract][Full Text] [Related]
45.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
46. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.
Nakahata Y; Sahar S; Astarita G; Kaluzova M; Sassone-Corsi P
Science; 2009 May; 324(5927):654-7. PubMed ID: 19286518
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
48. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
49. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
Gerner RR; Macheiner S; Reider S; Siegmund K; Grabherr F; Mayr L; Texler B; Moser P; Effenberger M; Schwaighofer H; Moschen AR; Kircher B; Oberacher H; Zeiser R; Tilg H; Nachbaur D
Leukemia; 2020 Jul; 34(7):1885-1897. PubMed ID: 31974433
[TBL] [Abstract][Full Text] [Related]
50. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
51. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
[TBL] [Abstract][Full Text] [Related]
52. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
53. Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.
Yang NC; Song TY; Chang YZ; Chen MY; Hu ML
Biogerontology; 2015 Feb; 16(1):31-42. PubMed ID: 25146190
[TBL] [Abstract][Full Text] [Related]
54. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
55. A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD
Silveira SC; Buhagiar-Labarchède G; Onclercq-Delic R; Gemble S; Bou Samra E; Mameri H; Duchambon P; Machon C; Guitton J; Amor-Guéret M
Sci Rep; 2020 Aug; 10(1):13907. PubMed ID: 32807821
[TBL] [Abstract][Full Text] [Related]
56. SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.
Sociali G; Grozio A; Caffa I; Schuster S; Becherini P; Damonte P; Sturla L; Fresia C; Passalacqua M; Mazzola F; Raffaelli N; Garten A; Kiess W; Cea M; Nencioni A; Bruzzone S
FASEB J; 2019 Mar; 33(3):3704-3717. PubMed ID: 30514106
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Bi TQ; Che XM; Liao XH; Zhang DJ; Long HL; Li HJ; Zhao W
Oncol Rep; 2011 Nov; 26(5):1251-7. PubMed ID: 21743967
[TBL] [Abstract][Full Text] [Related]
58. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
59. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase.
Burgos ES; Schramm VL
Biochemistry; 2008 Oct; 47(42):11086-96. PubMed ID: 18823127
[TBL] [Abstract][Full Text] [Related]
60. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
